Literature DB >> 29409820

Versatile redox-sensitive pullulan nanoparticles for enhanced liver targeting and efficient cancer therapy.

Liping Huang1, Birendra Chaurasiya2, Dawei Wu3, Huimin Wang2, Yunai Du2, Jiasheng Tu4, Thomas J Webster5, Chunmeng Sun6.   

Abstract

A reversibly disulfide-crosslinked pullulan nanoparticle with folic acid (FA) decoration (FA-Pull-LA CLNPs) was fabricated for dual-targeted and reduction-responsive anti-tumoral liver drug delivery based on the specific affinity of pullulan and FA to overexpress asialoglycoprtein receptors (ASGPR) and folate receptors (FR), respectively. Paclitaxel (PTX)-loaded FA-Pull-LA nanoparticles (NPs) with satisfactory size, polydispersity index (PDI), and zeta potential exhibited much faster PTX release in the presence of 10mM glutathione (GSH) rather than physiological conditions. In vitro cellular assays confirmed the dual targetability and endosomal accumulation of FA-Pull-LA NPs. In SMMC-7721 tumor-bearing mice, FA-Pull-LA-PTX CLNPs showed the strongest anti-tumor efficiency as well as the lowest toxicity among all three groups. Conclusively, the present study implied that reversibly crosslinked FA-Pull-LA NPs with dual-targeting capacity provided a stable and intelligent platform for efficient liver cancer therapy, which should be further studied for a wide range of anti-cancer applications.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Dual-targeting; Pullulan nanoparticles; Reduction-sensitive; Reversible disulfide-crosslinking

Mesh:

Substances:

Year:  2018        PMID: 29409820     DOI: 10.1016/j.nano.2018.01.015

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  6 in total

Review 1.  Active Cellular and Subcellular Targeting of Nanoparticles for Drug Delivery.

Authors:  Okhil K Nag; James B Delehanty
Journal:  Pharmaceutics       Date:  2019-10-18       Impact factor: 6.321

2.  Hyaluronic acid-modified redox-sensitive hybrid nanocomplex loading with siRNA for non-small-cell lung carcinoma therapy.

Authors:  Daoyuan Chen; Peng Zhang; Minghui Li; Congcong Li; Xiaoyan Lu; Yiying Sun; Kaoxiang Sun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  Multi-Stimuli-Responsive DOX Released from Magnetosome for Tumor Synergistic Theranostics.

Authors:  Ming-Fong Tsai; Yu-Lun Lo; Yuan-Chun Huang; Chun-Chieh Yu; Yi-Ting Wu; Chia-Hao Su; Li-Fang Wang
Journal:  Int J Nanomedicine       Date:  2020-11-05

4.  Enhanced cytotoxicity of a redox-sensitive hyaluronic acid-based nanomedicine toward different oncocytes via various internalization mechanisms.

Authors:  Yunai Du; Sheng Wang; Tianhao Zhang; Dongsheng He; Jiasheng Tu; Yan Shen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

5.  Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy.

Authors:  Liping Huang; Yanan Li; Yunai Du; Yiyi Zhang; Xiuxia Wang; Yuan Ding; Xiangliang Yang; Fanling Meng; Jiasheng Tu; Liang Luo; Chunmeng Sun
Journal:  Nat Commun       Date:  2019-10-25       Impact factor: 14.919

Review 6.  Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.

Authors:  Anita Bakrania; Gang Zheng; Mamatha Bhat
Journal:  Pharmaceutics       Date:  2021-12-25       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.